Core Viewpoint - Clearmind Medicine Inc. has announced the publication of an international patent application for a combination therapy aimed at treating metabolic syndrome and obesity, in collaboration with SciSparc Ltd. [1][2] Group 1: Patent and Collaboration - The patent application covers a combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) [2] - This collaboration has resulted in the filing of 13 patent families across multiple jurisdictions, including the United States, Europe, and China [4] - The focus of the collaboration is on developing therapies that combine neuroplastogens with N-acylethanolamines to address various health disorders [4] Group 2: Health Impact and Market Potential - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The proprietary combination therapy aims to leverage MEAI's pharmacological profile and PEA's anti-inflammatory properties to provide a safe and effective treatment for these health challenges [3] Group 3: Company Strategy and Intellectual Property - The company is committed to developing breakthrough therapies for complex health conditions, with a focus on metabolic syndrome and obesity [5] - Clearmind's intellectual property portfolio currently consists of 19 patent families, including 31 granted patents, with plans to seek additional patents as warranted [6]

Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a combination therapy aimed at addressing obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to tackle significant health issues, including alcohol use disorder [4] - The company currently holds a portfolio of nineteen patent families, which includes 31 granted patents, and plans to seek additional patents as necessary [5] Health Challenges Addressed - The proprietary combination therapy targets obesity, which affects over 890 million people globally, and MASLD, impacting more than 30% of the adult population [2] - The treatment options for these conditions remain limited despite their widespread prevalence [2] Therapeutic Approach - The combination therapy utilizes MEAI (5-methoxy-2-aminoindane) and Palmitoylethanolamide (PEA), leveraging MEAI's pharmacological profile and PEA's anti-inflammatory and neuroprotective properties [3] - The company believes this novel approach could provide a safe and effective therapeutic alternative for patients [3] Collaboration - The patent filing is part of an ongoing collaboration with SciSparc Ltd., which is also focused on developing therapies for central nervous system disorders [3]

Core Insights - SciSparc Ltd. has filed a new international patent application in collaboration with Clearmind Medicine Inc. for a combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is currently developing drugs such as SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus [4] Industry Context - Obesity affects over 890 million people globally and is a significant risk factor for chronic conditions, while non-alcoholic fatty liver disease (NAFLD) impacts more than 30% of the adult population [2] - There is a limited number of treatment options available for these health challenges, highlighting the potential market opportunity for innovative therapies [2]

Core Insights - Clearmind Medicine Inc. has successfully completed site initiation at Tel Aviv Sourasky Medical Center for its Phase I/IIa clinical trial of CMND-100, targeting Alcohol Use Disorder (AUD) [1][2] - The trial is multinational and multi-center, assessing safety, tolerability, and pharmacokinetics of CMND-100, while also exploring early efficacy signals [2][3] - CMND-100 utilizes the molecule 5-methoxy-2-aminoindane (MEAI) and has shown promising preclinical results in reducing alcohol cravings, addressing a significant unmet need in AUD treatment [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents [5] Clinical Trial Details - The Phase I/IIa trial includes prestigious sites such as Yale School of Medicine and Johns Hopkins University, alongside TASMC and Hadassah-University Medical Center [2] - The trial is led by Prof. David Zeltser at TASMC, enhancing Clearmind's clinical network and patient enrollment [2][3]

Core Viewpoint - Clearmind Medicine Inc. is expanding its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder (AUD), by activating a new site at Johns Hopkins University and enrolling its first participant there, indicating positive momentum in its clinical development program [1][2][3]. Group 1: Clinical Trial Details - The Phase I/IIa clinical trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy indicators focusing on reducing alcohol cravings and consumption [2][4]. - The trial is a multinational, multicenter study that will explore early signals of efficacy, including reductions in alcohol consumption and cravings, which could facilitate further development of this therapy [4]. Group 2: Company Strategy and Goals - The activation of new clinical sites and participant enrollment is seen as a step closer to validating CMND-100's potential to transform the treatment landscape for AUD, reflecting the scientific community's interest in the company's approach [3][5]. - Clearmind's primary objective is to research and develop psychedelic-based compounds and commercialize them as regulated medicines, foods, or supplements, addressing widespread and underserved health problems [5]. Group 3: Intellectual Property - The company currently holds an intellectual portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents for its compounds as warranted [6].

Core Viewpoint - Clearmind Medicine Inc. has received Institutional Review Board (IRB) approval for its Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][3][4] Group 1: Clinical Trial Details - The trial will take place at Tel Aviv Sourasky Medical Center (TASMC) and includes participation from other prestigious institutions such as Yale School of Medicine and Johns Hopkins University [2] - The trial aims to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD [4] Group 2: Company Background and Objectives - Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6] Group 3: Market Context and Impact - AUD is a significant global health issue, accounting for 4.7% of all deaths worldwide, highlighting the urgent need for effective treatments [4] - The company aims to provide a transformative treatment for individuals affected by AUD, which impacts millions of lives globally [4]

Core Viewpoint - Clearmind Medicine Inc. has achieved a significant milestone by dosing the first participant with its proprietary drug candidate CMND-100 in a Phase I/IIa clinical trial aimed at treating Alcohol Use Disorder (AUD) [1][3]. Group 1: Clinical Trial Details - The Phase I/IIa trial is being conducted at prestigious clinical sites, including Yale School of Medicine, Johns Hopkins University, and medical centers in Israel [2]. - The trial's objectives include evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, as well as assessing its preliminary efficacy in reducing alcohol cravings and consumption [2][3]. - This trial represents the first time Clearmind's neuroplastogen compound has been administered to humans in a controlled clinical setting [3]. Group 2: Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, particularly AUD [4]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].

Core Insights - Clearmind Medicine Inc. has added Hadassah-University Medical Center in Jerusalem as a new clinical site for its Phase I/IIa trial of CMND-100, a drug candidate for Alcohol Use Disorder (AUD) [1][2] - The trial aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100, while also assessing its potential to reduce alcohol cravings and consumption [3] - Alcohol Use Disorder affects over 280 million people globally, indicating a significant unmet medical need and a potential multibillion-dollar market opportunity [4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [7] Clinical Trial Details - The inclusion of Hadassah-University Medical Center is expected to enhance patient recruitment, accelerate data collection, and increase the statistical power of the study [3][5] - Other participating institutions include Yale School of Medicine, Johns Hopkins University, and Tel Aviv Sourasky Medical Center [2]

Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD), which affects hundreds of millions globally [1][2] - The trial's primary focus is on evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to determine its potential in reducing alcohol cravings and consumption [2] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel psychedelic-derived therapeutics to address significant health issues, including AUD [4] - The company has a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] Market Potential - The substance use disorder treatment market in the U.S. was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, indicating a significant opportunity for innovative treatments like CMND-100 [3]

Core Viewpoint - Clearmind Medicine Inc. has expanded its Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center as a clinical site, following the enrollment of the first patient [1][3]. Group 1: Clinical Trial Expansion - The addition of Tel Aviv Sourasky Medical Center, led by Dr. David Zeltser, enhances the trial's capacity to evaluate CMND-100's safety, tolerability, and pharmacokinetic profile [2]. - Other prestigious institutions involved in the trial include Yale School of Medicine and Johns Hopkins University, indicating a strong clinical network [2][3]. Group 2: Company Objectives and Focus - Clearmind is focused on developing novel psychedelic-derived therapeutics to address major under-treated health issues, particularly AUD, which affects millions and is responsible for 2.6 million deaths annually [3][4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents to strengthen its position [5].